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A DOG’S TALE
The Veterinary Clinical  
Investigations Center in Action
BY ELLEN LYON
Dr. Dorothy Cimino 
Brown with Rocky, a past 
participant in a VCIC pain 
management study.
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L ast summer Jeff Gillman noticed that his German shepherd mix, Reuben, had lost a lot of weight. After examining the dog, Reuben’s veterinarian told Gillman to take him to a specialty animal hospital 
right away. Gillman knew just where to go: Penn Vet’s 
Ryan Hospital. “It’s the best emergency hospital,” he said.
Penn veterinarians removed Reuben’s spleen and 
did a biopsy. Back came the dreaded diagnosis of 
hemangiosarcoma, an aggressive cancer of the blood vessels, 
and a grim prognosis of two-to-four months without 
treatment and four-to-six months with chemotherapy.
“I was crushed, absolutely crushed,” Gillman said. A 
dozen years earlier he had picked Reuben from a litter 
of puppies at a farmers market in Santa Cruz. Reuben 
rode in Gillman’s backpack, with his paws hanging out, as 
they traveled the West Coast that summer after Gillman’s 
freshman year of college. “At this point, he’s one of my 
oldest friends,” Gillman said.
So Gillman leapt at the opportunity when the 
veterinarians at Ryan Hospital told him about a study 
Reuben could participate in through Penn Vet’s Veterinary 
Clinical Investigations Center (VCIC). The study compares 
the effects of the traditional Chinese medicine I’m-Yunity, a 
compound derived from the Coriolus versicolor mushroom, 
to standard chemotherapy treatment on survival time and 
quality of life for dogs with splenic hemangiosarcoma. 
Dr. Dorothy Cimino 
Brown is director 
of the VCIC and a 
board-certified small 
animal surgeon. In a 
published study, Brown 
and Jennifer Reetz, an 
attending radiologist, 
showed that dogs with 
hemangiosarcoma that 
were treated with I’m-
Yunity had the longest 
survival time reported 
for dogs with the 
disease. The VCIC is 
collaborating on 
the study with a 
Chinese company 
that seeks to 
apply the Western 
scientific method to 
Eastern medicine.
Reuben’s study 
is divided into three 
groups. One group 
is being treated with 
chemotherapy alone. 
A second group is 
being treated with I’m-Yunity alone. And a third group 
is being treated with both chemotherapy and I’m-Yunity. 
Gillman doesn’t know which group Reuben is in, but he 
believes it’s one of the groups getting I’m-Yunity. It has 
been a year since Reuben’s diagnosis, and he’s still going 
strong.  
The VCIC was created in 2005 to support Penn Vet 
investigators engaged in clinical research and to coordinate 
clinical trials of novel approaches for treating, managing, and 
preventing disease in animals. 
“I love research and solving problems to make life 
better,” said Penn Vet Dean Joan Hendricks, who founded 
the VCIC. Section chief for critical care at Ryan Hospital 
at the time, she envisioned a research center where 
“our animal patients might be able to get access to new 
treatments and interventions,” often at less or no expense 
to the client. And the infrastructure would assist Penn Vet 
investigators with monitoring their subjects and meeting 
regulatory requirements, she said.
The center would translate research on novel treatments 
that began in lab animal studies to trials in companion 
animals that develop many of the same diseases as people. 
The VCIC’s first clinical trial was sponsored by Pfizer 
Animal Health, the result of an idea pitched to them by 
Hendricks. After nearly two years of negotiations, Hendricks 
felt confident that the VCIC model would work. “We 
always made sure there was something we could publish, no 
matter what,” she noted.
“While all VCIC studies have direct applications to animal health, 
about half the trials running now have sponsors that are ultimately 
interested in application of the results to human health as well.” 
— Dr. Dorothy Cimino Brown, Director of Penn Vet’s Veterinary Clinical Investigations Center





nurse Rene Newman, 
CVT, prepares a 
sedated dog for an 
elbow injection in a 
stem cell study.
But Hendricks worried about the clients. Would they 
understand the risks and the lack of guarantees for their 
beloved pets? To ensure that clients do, VCIC staff conducts 
a rigorous informed-consent process, and Hendricks has 
been overwhelmed by their altruistic attitude. “It’s very 
important to them that their pet helps another animal. They 
go into it with their eyes open,” she said. 
In addition, clients’ pets are “getting access to potential 
interventions that they wouldn’t otherwise have access to 
anywhere else,” Brown noted. In post-study surveys, clients 
routinely say they appreciate the frequent contact they have 
with the clinical trials nurses, including being given cell 
phone numbers if they have questions or problems. 
Gillman sounded pleased about the care Reuben receives 
as part of the I’m-Yunity study. “He goes there and he has a 
nurse. They treat him like he’s the only [patient],” Gillman 
said.
More than three-fourths of clients participating in VCIC 
studies are new to Penn Vet, Brown noted. At the end of 
their studies, more than 90 percent say they would consider 
returning.
The VCIC began with one principal investigator 
(Brown), one veterinary nurse, and one study. It has grown 
to include the participation of dozens of investigators aided 
by five veterinary clinical trials nurses. 
Brown is responsible for one of the VCIC’s biggest 
successes so far. She collaborated with Dr. Michael Iadarola 
to study resiniferatoxin (RTX)—a naturally occurring 
substance from a Moroccan cactus-like succulent plant—as 
a potential treatment for chronic pain from canine bone 
cancer. They gave dogs one injection of RTX into the fluid 
around the spinal cord. 
“The effect was stunning,” said Iadarola, a senior research 
scientist at the National Institutes of Health. An article from 
the May-June 2006 NIH Catalyst noted that: “All of the 
dogs experienced significant pain relief that lasted for the 
rest of their lives.” 
Iadarola said such results with dogs provided a 
“tremendous incentive” to move to human trials—the first 
of which, involving patients with advanced cancer, is going 
on now. RTX initially had been tested on rodents. “To go 
directly from the rat to the human was a pretty big step,” he 
said. Often such large leaps in drug testing result in a high 
failure rate, Brown said, because the pre-clinical models 
don’t mimic what goes on with people, and the disease is 
artificially induced in the rodents. 
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But when testing makes a stop in between 
with companion animals, they “share the same 
environment [with humans]. Many of the same risk 
factors are going to be present as in people,” Brown 
said. That makes the results more likely to be 
replicable in humans. As Hendricks noted, the loss 
of laboratory conditions “makes the science much 
harder and much, much closer to reality.” 
Studies with companion animals also allow 
researchers to better gauge a drug’s possible side 
effects. Owners can assess their dog’s pain, bladder 
and bowel function, and activity level at home, and 
notice any personality changes, Iadarola said.
It is a natural progression for the only veterinary 
school in the country founded through a medical 
school to also be the first to create a research facility 
dedicated to translational research. The VCIC 
exemplifies Penn Vet’s longstanding commitment 
to One Health, which aims to advance health care 
and well-being for animals and humans through 
collaborative, interdisciplinary practices. The VCIC’s 
goal is to get cutting-edge therapies to patients—
both animal and human—as efficiently as possible. 
The VCIC has completed 46 studies, according 
to Managing Director Michael DiGregorio. 
Currently, 19 trials involving 18 faculty members are 
underway, and another six trials are being planned. 
While all VCIC studies have applications to animal 
health, about half the trials running now have 
sponsors that are ultimately interested in application 
of the results to human health as well, Brown said.  
Industry representatives, government 
organizations, individuals, and foundations fund 
the VCIC’s studies, DiGregorio said. Subjects are 
recruited using traditional advertising, web and 
social media, and through the network of more than 
3,000 veterinary practices that refer the pets that 
make the 30,000 visits to Ryan Hospital each year.
The VCIC recently finished its first large animal 
study at New Bolton Center, which looked at a 
novel estrus synchronization protocol in cows. 
Another large animal trial—studying risk assessment 
of cross-contamination among different species 
including cows, goats, and sheep—is underway, 
DiGregorio said.
Gillman finds universal and personal value in the 
VCIC’s work. Reuben’s participation in a study 
may lead to better prognoses for dogs with the same 
kind of cancer in the future. “I’m glad that Reuben 
gets to help. We take that seriously,” Gillman said. 
“I think the study has been a blessing. I don’t think 
that he would have lasted a year. The study has 
allowed me to really cherish and enjoy him.”
ANIMALS SOUGHT FOR  
VCIC CLINICAL TRIALS
Plant-Derived Supplements to  
Boost Quality of Life in Geriatric Dogs
ELIGIBILITY: 10 years of age or older; not on any medication
BENEFITS: Study visits; blood work; $100 gift card on 
completion of all study visits
Stem Cell Therapy for Dogs  
with Elbow Dysplasia (FMCP form)
ELIGIBILITY: Diagnosis of fragmented medial coronoid 
processes (FMCPs); younger than 2 years; weighs at least 
33 pounds; clinical signs of arthritis
BENEFITS: Orthopedic exams; arthroscopic surgery and 
removal of FMCPs; adjunctive stem cell or hyaluronic acid 
therapy; follow-up care for one year
Palladia® for Dogs with  
Appendicular Osteosarcoma
This trial is an option for owners who decline 
chemotherapy, but want to try to control cancer  
using oral medication at home.
ELIGIBILITY: Diagnosis of OSA; no metastasis to lungs
BENEFITS: Study-related costs; blood work and chest 
radiographs; study drug and supportive medications
Comparison of Three New Chemotherapy  
Drugs for Dogs with Lymphoma
ELIGIBILITY: Diagnosis of multi-centric lymphoma; weighs 
at least 33 pounds; not receiving treatment for lymphoma
BENEFITS: Study visits and treatments; $1,000 towards 
future care at Penn Vet
For more information on these and other studies,  
visit www.vet.upenn.edu/vcic, call 215-573-0302,  
or email vcic@vet.upenn.edu 
Follow VCIC on Twitter @PennVet_VCIC
